BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy

Saved in:
Bibliographic Details
Published inClinical breast cancer Vol. 18; no. 2; pp. 184 - 188
Main Authors Gornstein, Erica L., Sandefur, Sara, Chung, Jon H., Gay, Laurie M., Holmes, Oliver, Erlich, Rachel L., Soman, Salil, Martin, L. Katherine, Rose, Andrea V., Stephens, Philip J., Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Blau, Sibel
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2018
Subjects
BRCA reversion
BRCA2 Protein - genetics
Breast Neoplasms - blood
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Circulating tumor DNA
ctDNA
Disease Progression
DNA Mutational Analysis
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
Fatal Outcome
Female
Germ-Line Mutation - drug effects
Humans
Liquid Biopsy
Liver - pathology
Liver Neoplasms - blood
Liver Neoplasms - drug therapy
Liver Neoplasms - pathology
Liver Neoplasms - secondary
Loss of Heterozygosity
Metastatic breast cancer
Middle Aged
PARP inhibitor
Phthalazines - pharmacology
Phthalazines - therapeutic use
Piperazines - pharmacology
Piperazines - therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Receptors, Estrogen - metabolism
Metastatic breast cancer
BRCA reversion
Circulating tumor DNA
ctDNA
PARP inhibitor
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1526-8209
1938-0666
DOI:10.1016/j.clbc.2017.12.010